Category:Barbiturates - Revision history

MDElliottMD: Phase 2 retag: add Pharmaceutical root parent (taxonomy restructure 2026-05-20)

2026-05-19T19:22:04Z

Phase 2 retag: add Pharmaceutical root parent (taxonomy restructure 2026-05-20)

← Older revision		Revision as of 19:22, 19 May 2026
Line 36:		Line 36:
	[[Category:MedCategory]]		[[Category:MedCategory]]
	[[Category:MedCategoryFull]]		[[Category:MedCategoryFull]]
			[[Category:Pharmaceutical]]

MDElliottMD: Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

2026-05-19T03:16:13Z

Em-dash sweep: replace em-dash with comma per project rule; PendellsCorner verbatim quotes preserved.

← Older revision		Revision as of 03:16, 19 May 2026
Line 4:		Line 4:
	The story begins in 1864, when the German chemist Adolf von Baeyer synthesized a new compound, barbituric acid, from urea and a derivative of malonic acid. The name's origin is uncertain and has attracted several colourful stories, most involving the name Barbara; what is not in doubt is that the compound itself had no obvious medical use, and von Baeyer set it aside.<ref name="lopez">López-Muñoz F, Ucha-Udabe R, Álamo C. The history of barbiturates a century after their clinical introduction. ''Neuropsychiatr Dis Treat.'' 2005;1(4):329–343. PMID 18568113.</ref>		The story begins in 1864, when the German chemist Adolf von Baeyer synthesized a new compound, barbituric acid, from urea and a derivative of malonic acid. The name's origin is uncertain and has attracted several colourful stories, most involving the name Barbara; what is not in doubt is that the compound itself had no obvious medical use, and von Baeyer set it aside.<ref name="lopez">López-Muñoz F, Ucha-Udabe R, Álamo C. The history of barbiturates a century after their clinical introduction. ''Neuropsychiatr Dis Treat.'' 2005;1(4):329–343. PMID 18568113.</ref>

	Nearly four decades passed before barbituric acid yielded a medicine. In 1903 the chemist Emil Fischer — once von Baeyer's assistant — and the physician Joseph von Mering found that one derivative, diethylbarbituric acid, was a powerful sedative, far more effective at inducing sleep in dogs than the remedies then in use. It was brought to market by Bayer as Veronal, the first barbiturate medicine; the name is usually said to derive from the Italian city of Verona, though this too is disputed.<ref name="lopez"/> A second early barbiturate of lasting importance, [[phenobarbital]], followed from Bayer in 1912.		Nearly four decades passed before barbituric acid yielded a medicine. In 1903 the chemist Emil Fischer, once von Baeyer's assistant, and the physician Joseph von Mering found that one derivative, diethylbarbituric acid, was a powerful sedative, far more effective at inducing sleep in dogs than the remedies then in use. It was brought to market by Bayer as Veronal, the first barbiturate medicine; the name is usually said to derive from the Italian city of Verona, though this too is disputed.<ref name="lopez"/> A second early barbiturate of lasting importance, [[phenobarbital]], followed from Bayer in 1912.

	== The barbiturate era ==		== The barbiturate era ==
	Veronal was the beginning of an era. Over the following decades dozens of barbiturates were developed and marketed, differing chiefly in how quickly they acted and how long their effects lasted. They were used as sedatives to calm anxiety, as hypnotics to induce sleep, in psychiatry for so-called "sleep cure" treatments, and — in the case of [[phenobarbital]] — as a genuine and lasting advance in the treatment of epilepsy, a use that continues today. Short-acting barbiturates such as [[thiopental]] became important in anaesthesia.<ref name="lopez"/>		Veronal was the beginning of an era. Over the following decades dozens of barbiturates were developed and marketed, differing chiefly in how quickly they acted and how long their effects lasted. They were used as sedatives to calm anxiety, as hypnotics to induce sleep, in psychiatry for so-called "sleep cure" treatments, and, in the case of [[phenobarbital]], as a genuine and lasting advance in the treatment of epilepsy, a use that continues today. Short-acting barbiturates such as [[thiopental]] became important in anaesthesia.<ref name="lopez"/>

	By the 1930s and 1940s the barbiturates had reached their greatest popularity, occupying a place in medicine comparable to the one the [[:Category:Benzodiazepines\|benzodiazepines]] would later hold.<ref name="lopez"/> Production was vast: at the peak, billions of tablets were made each year in the United States alone. They became part of the texture of mid-century life — known colloquially as "goofballs" or "downers", widely prescribed, easily obtained, and used both medically and recreationally.		By the 1930s and 1940s the barbiturates had reached their greatest popularity, occupying a place in medicine comparable to the one the [[:Category:Benzodiazepines\|benzodiazepines]] would later hold.<ref name="lopez"/> Production was vast: at the peak, billions of tablets were made each year in the United States alone. They became part of the texture of mid-century life, known colloquially as "goofballs" or "downers", widely prescribed, easily obtained, and used both medically and recreationally.

	== The reckoning ==		== The reckoning ==
	The drawbacks of the barbiturates were serious and, ultimately, could not be designed away. They carried a high risk of dependence, and a withdrawal syndrome that could be severe. Most dangerous of all was the narrow margin between an effective dose and a lethal one: barbiturates depress breathing, and an overdose — taken alone, or in combination with alcohol — could be fatal, with no antidote available.<ref name="lopez"/>		The drawbacks of the barbiturates were serious and, ultimately, could not be designed away. They carried a high risk of dependence, and a withdrawal syndrome that could be severe. Most dangerous of all was the narrow margin between an effective dose and a lethal one: barbiturates depress breathing, and an overdose, taken alone, or in combination with alcohol, could be fatal, with no antidote available.<ref name="lopez"/>

	Through the 1950s and 1960s, deaths from barbiturate overdose, both accidental and deliberate, rose into a recognized public-health problem; the death of the actress Marilyn Monroe in 1962 from barbiturate poisoning brought wide public attention to the danger.<ref name="campbell">Campbell G, Darke S, Hall W, Lappin J. Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia? ''Addiction.'' 2021;116(12):3273–3275. PMID 34382271.</ref> Public campaigns arose to restrict the drugs, and barbiturates were brought under tightened legal control. In the United States, they were scheduled under the Controlled Substances Act of 1970.<ref name="lopez"/>		Through the 1950s and 1960s, deaths from barbiturate overdose, both accidental and deliberate, rose into a recognized public-health problem; the death of the actress Marilyn Monroe in 1962 from barbiturate poisoning brought wide public attention to the danger.<ref name="campbell">Campbell G, Darke S, Hall W, Lappin J. Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia? ''Addiction.'' 2021;116(12):3273–3275. PMID 34382271.</ref> Public campaigns arose to restrict the drugs, and barbiturates were brought under tightened legal control. In the United States, they were scheduled under the Controlled Substances Act of 1970.<ref name="lopez"/>
Line 19:		Line 19:

	== Modern use ==		== Modern use ==
	Barbiturates have not vanished from medicine, but their role is now narrow and specific. [[phenobarbital]] and [[primidone]] remain in use as [[:Category:Anticonvulsants\|anticonvulsants]]; [[phenobarbital]] also has a role in managing withdrawal from sedatives. Short-acting agents such as [[thiopental]] have been used in anaesthesia, though here too newer medicines have displaced them. Barbiturates also have non-medical applications, including in euthanasia and, in some jurisdictions, in capital punishment. For the everyday treatment of anxiety and sleeplessness — the use that once made them ubiquitous — they have been almost entirely superseded.		Barbiturates have not vanished from medicine, but their role is now narrow and specific. [[phenobarbital]] and [[primidone]] remain in use as [[:Category:Anticonvulsants\|anticonvulsants]]; [[phenobarbital]] also has a role in managing withdrawal from sedatives. Short-acting agents such as [[thiopental]] have been used in anaesthesia, though here too newer medicines have displaced them. Barbiturates also have non-medical applications, including in euthanasia and, in some jurisdictions, in capital punishment. For the everyday treatment of anxiety and sleeplessness, the use that once made them ubiquitous, they have been almost entirely superseded.

	== Mechanisms ==		== Mechanisms ==
	Barbiturates are understood to act chiefly at the GABA-A receptor, the receptor for the brain's principal inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Like the [[:Category:Benzodiazepines\|benzodiazepines]], they enhance GABA's inhibitory effect — but they do so differently, and the difference matters: at higher concentrations barbiturates can activate the receptor directly, even without GABA present. This is understood to be a major reason barbiturates are more dangerous in overdose than benzodiazepines, whose action depends on GABA already being present and so has more of a ceiling. That barbiturates act at the GABA-A receptor is well established; the fuller relationship between that action and the range of their effects is more complex and remains a subject of research.		Barbiturates are understood to act chiefly at the GABA-A receptor, the receptor for the brain's principal inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Like the [[:Category:Benzodiazepines\|benzodiazepines]], they enhance GABA's inhibitory effect, but they do so differently, and the difference matters: at higher concentrations barbiturates can activate the receptor directly, even without GABA present. This is understood to be a major reason barbiturates are more dangerous in overdose than benzodiazepines, whose action depends on GABA already being present and so has more of a ceiling. That barbiturates act at the GABA-A receptor is well established; the fuller relationship between that action and the range of their effects is more complex and remains a subject of research.

	== Members ==		== Members ==
Line 28:		Line 28:

	== Safety ==		== Safety ==
	The defining hazard of the barbiturates is the narrow margin between a therapeutic dose and a dangerous one. They depress breathing, and in overdose — particularly in combination with alcohol or other central nervous system depressants — this can be fatal; unlike for some other sedatives, there is no specific antidote. Regular use leads readily to tolerance and to physical dependence, and the withdrawal syndrome can be severe, in serious cases including seizures, so that barbiturates are not stopped abruptly after sustained use. It was this combination of properties — a high risk of dependence and a genuine risk of death in overdose — that led barbiturates to be displaced, for most purposes, by medicines with a wider margin of safety. Figures for these risks are population estimates that vary between studies, and individual response varies considerably between people.		The defining hazard of the barbiturates is the narrow margin between a therapeutic dose and a dangerous one. They depress breathing, and in overdose, particularly in combination with alcohol or other central nervous system depressants, this can be fatal; unlike for some other sedatives, there is no specific antidote. Regular use leads readily to tolerance and to physical dependence, and the withdrawal syndrome can be severe, in serious cases including seizures, so that barbiturates are not stopped abruptly after sustained use. It was this combination of properties, a high risk of dependence and a genuine risk of death in overdose, that led barbiturates to be displaced, for most purposes, by medicines with a wider margin of safety. Figures for these risks are population estimates that vary between studies, and individual response varies considerably between people.

	== References ==		== References ==

MDElliottMD: Replace stub with full Barbiturates category page

2026-05-18T01:26:24Z

Replace stub with full Barbiturates category page

@@ Line 1: / Line 1: @@
-This category groups medicines belonging to the [[Classes|Barbiturates]] class. See [[Classes]] for the full taxonomy.
+The barbiturates are a class of medicines that depress the central nervous system, used for much of the twentieth century as [[:Category:Sedative-Hypnotics|sedatives]], sleeping medicines, and [[:Category:Anticonvulsants|anticonvulsants]]. For roughly the first half of that century they were among the most widely used medicines in the world. Their history is a particularly stark instance of a pattern that recurs across the history of medicine: introduced as the safe and modern answer to the dangers of an older remedy, they were used enormously, were found to carry grave dangers of their own, and were in turn displaced by a new class advertised as safer still.
 [[Category:MedCategory]]
-[[Category:Anxiolytics & Sedative-Hypnotics]]
+[[Category:MedCategoryFull]]

MDElliottMD: Set parent categories: Anxiolytics & Sedative-Hypnotics

2026-05-15T16:07:20Z

Set parent categories: Anxiolytics & Sedative-Hypnotics

← Older revision		Revision as of 16:07, 15 May 2026
Line 2:		Line 2:

	[[Category:MedCategory]]		[[Category:MedCategory]]
			[[Category:Anxiolytics & Sedative-Hypnotics]]

MDElliottMD: Pharmacopedia: seed interaction class category

2026-05-14T01:10:06Z

Pharmacopedia: seed interaction class category

New page

This category groups medicines belonging to the [[Classes|Barbiturates]] class. See [[Classes]] for the full taxonomy.

[[Category:MedCategory]]